Executive Summary
Instem Life Science Systems plc is a leading supplier of IT solutions to the global drug and chemical development market. The Group is focussed on the early development stages, from late discovery and lead optimisation through to Phase I clinical evaluation. Instems solutions, part of the Early Development Application (EDA) market, increase productivity and automate the processes that lead to safer and more effective drug and chemical products. The Groups lead product suite, Provantis, is the market leading application in the Early Development Safety Assessment (EDSA) market. As the number one global provider, management estimates that approximately half of the worlds pre-clinical drug safety data has been collected over the last 20 years using Instem software. Currently Instem has over 80 customers in North America, Europe, China, India and Japan. Its blue chip customer base consists of the leading pharmaceutical, chemical and contract research organisations as well as academic, government and privately funded research institutions across a number of sites worldwide. These include seven of the top ten pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. Instem employs over 100 people across 8 locations around the world. The Groups US headquarters are in Conshohocken, near Philadelphia in the heart of a cluster of pharmaceutical companies and CROs. There are also sales and support offices in Michigan, New Jersey and Kansas City. Its European headquarters are in Stone, Staffordshire and the Company has a technology support centre in Liverpool. As part of its geographic expansion, Instem has also recently established direct sales and development teams in China and India. This physical presence gives the company a key competitive advantage over its rivals who operate in such locations on a remote basis. The business now aims to accelerate its growth trajectory, both organically by expanding its core product range, developing new solutions for the Early Development market, extending its presence in Asia and, where appropriate, via selective acquisitions of complementary or competitor businesses.
